[{"orgOrder":0,"company":"Second Affiliated Hospital, Zhejiang University","sponsor":"National Clinical Research Center, Southern Medical University | Ningbo Yinzhou Community Health Service Center","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Enalapril Maleate","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Second Affiliated Hospital, Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Second Affiliated Hospital, Zhejiang University \/ National Clinical Research Center, Southern Medical University | Ningbo Yinzhou Community Health Service Center","highestDevelopmentStatusID":"10","companyTruncated":"Second Affiliated Hospital, Zhejiang University \/ National Clinical Research Center, Southern Medical University | Ningbo Yinzhou Community Health Service Center"},{"orgOrder":0,"company":"Ministry of Health, Sri Lanka","sponsor":"World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SRI LANKA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Enalapril Maleate","moa":"Angiotensin-converting enzyme","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Ministry of Health, Sri Lanka","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ministry of Health, Sri Lanka \/ World Health Organization","highestDevelopmentStatusID":"7","companyTruncated":"Ministry of Health, Sri Lanka \/ World Health Organization"},{"orgOrder":0,"company":"University Hospital, Clermont-Ferrand","sponsor":"Servier | LivaNova","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Enalapril Maleate","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"University Hospital, Clermont-Ferrand","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Clermont-Ferrand \/ Servier | LivaNova","highestDevelopmentStatusID":"10","companyTruncated":"University Hospital, Clermont-Ferrand \/ Servier | LivaNova"},{"orgOrder":0,"company":"Ethicare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Enalapril Maleate","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Ethicare","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ethicare \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ethicare \/ Undisclosed"},{"orgOrder":0,"company":"Ethicare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Enalapril Maleate","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Ethicare","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ethicare \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ethicare \/ Undisclosed"},{"orgOrder":0,"company":"Ethicare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Enalapril Maleate","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Ethicare","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ethicare \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ethicare \/ Undisclosed"},{"orgOrder":0,"company":"Ethicare","sponsor":"European Commission","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Enalapril Maleate","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Ethicare","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ethicare \/ European Commission","highestDevelopmentStatusID":"9","companyTruncated":"Ethicare \/ European Commission"},{"orgOrder":0,"company":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Enalapril Maleate","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ ZonMw","highestDevelopmentStatusID":"11","companyTruncated":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ ZonMw"},{"orgOrder":0,"company":"Shenzhen Ausa Pharmed Co.,Ltd","sponsor":"Nanfang Hospital, Southern Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Enalapril Maleate","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Shenzhen Ausa Pharmed Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shenzhen Ausa Pharmed Co.,Ltd \/ Nanfang Hospital, Southern Medical University","highestDevelopmentStatusID":"11","companyTruncated":"Shenzhen Ausa Pharmed Co.,Ltd \/ Nanfang Hospital, Southern Medical University"},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Azurity Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Enalapril Maleate","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Arbor Pharmaceuticals \/ Azurity Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Arbor Pharmaceuticals \/ Azurity Pharma"}]

Find Clinical Drug Pipeline Developments & Deals for Enalapril Maleate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : The combined company, operating as Azurity, will have a portfolio of products serving the unmet needs of patients in the cardiovascular, central nervous system, endocrinological, gastrointestinal, and institutional markets with many products like Epaned.

                          Product Name : Epaned

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          August 24, 2021

                          Lead Product(s) : Enalapril Maleate

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Azurity Pharma

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          02

                          Second Affiliated Hospital, Zhejiang University

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Second Affiliated Hospital, Zhejiang University

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Lead Product(s) : Enalapril Maleate

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Study Phase : Phase III

                          Sponsor : National Clinical Research Center, Southern Medical University | Ningbo Yinzhou Community Health Service Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Enalapril is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypertension.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 07, 2021

                          Lead Product(s) : Enalapril Maleate

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : National Clinical Research Center, Southern Medical University | Ningbo Yinzhou Community Health Service Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Ethicare

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Ethicare

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Enalapril is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Heart Failure.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 13, 2016

                          Lead Product(s) : Enalapril Maleate

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Ethicare

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Ethicare

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Enalapril is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Heart Failure.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 12, 2016

                          Lead Product(s) : Enalapril Maleate

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Ethicare

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Ethicare

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Enalapril is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Heart Failure.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 12, 2016

                          Lead Product(s) : Enalapril Maleate

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Ethicare

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Ethicare

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Enalapril is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Heart Failure.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 30, 2014

                          Lead Product(s) : Enalapril Maleate

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : European Commission

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Enalapril is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Essential Hypertension.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 12, 2014

                          Lead Product(s) : Enalapril Maleate

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : ZonMw

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Shenzhen Ausa Pharmed Co.,Ltd

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Shenzhen Ausa Pharmed Co.,Ltd

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Enalapril Maleate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypertension.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 07, 2013

                          Lead Product(s) : Enalapril Maleate

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Nanfang Hospital, Southern Medical University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Ministry of Health, Sri Lanka

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Ministry of Health, Sri Lanka

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Enalapril is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Renal Insufficiency, Chronic.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 20, 2012

                          Lead Product(s) : Enalapril Maleate

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : World Health Organization

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          University Hospital, Clermont-Ferrand

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          University Hospital, Clermont-Ferrand

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Enalapril is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heart Failure.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 20, 2011

                          Lead Product(s) : Enalapril Maleate

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Servier | LivaNova

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank